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Abstract Diabetic retinopathy (DR) is the foremost cause
of blindness in working-aged worldwide; it is characterized
by vascular and neuronal degeneration. Features of DR
include leukocyte adhesion, increased vascular permeabil-
ity, neovascularization and neuronal cell death. Early
diagnosis and intervention are important to prevent or at
least ameliorate the development of DR. Recent reports
indicate that pathophysiological mechanisms leading to
diabetic retinopathy include oxidative stress and retinal cell
death cascades. Circulating biomarkers of oxidative stress
such as malondialdehyde (MDA), thiobarbituric acid react-
ing substances (TBARS), conjugated diene (CD), advanced
oxidation protein products (AOPP), protein carbonyl, 8-
hydroxydeoxyguanosin (8-OHdG), nitrotyrosine, and F(2)
isoprostanes and pro-apoptosis molecules (caspase-3, Fas,
and Bax) are associated with increased susceptibility to
develop DR in diabetic subjects. Thus, identification of
oxidative stress and cell death biomarkers in diabetic
patients could be in favor of predicting, diagnosis, and
prevention of DR, and to target for novel therapeutic
interventions.
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Diabetic retinopathy is a vision-threatening disease char-
acterized by neurodegenerative features associated with
extensive vascular changes. It remains unclear how these
pathologies relate to each other and their net contribution to
retinal damage. There are multiple biochemical pathways
which contribute to the development of the neurovascular
injury in DR. As a result, biomarkers which reflect different
pathways are released locally and into the circulation. Early
identification of these biomarkers could be in favor of
predicting and efficient management of DR. Among these
biomarkers are the ones related to inflammatory response,
oxidative stress and retinal cell death. Diabetes increases
oxidative stress, which plays a key regulatory role in the
development of its complications [1, 2]. Hyperglycemia-
induced reactive oxygen species (ROS) generation is
considered a causal link between elevated glucose and the
pathways of development of diabetic complications [3].
Oxidative stress may lead to cell death [4] via apoptotic
means. Apoptosis of retinal neurons particularly ganglion
cells [5–7] has been demonstrated in diabetic retinopathy as
demonstrated by profound retinal abnormalities, evaluated
by electroretinography, and potential visual changes evoked
before the onset of the first vascular change is detectable in
the diabetic retina [8, 9]. Retinal capillary cells also
undergo accelerated apoptosis, which precedes the detec-
tion of any histopathological changes characteristic of
diabetic retinopathy [10]. The current review discusses the
markers of oxidative stress and retinal cell death associated
with DR.
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Oxidative stress and diabetic retinopathy
Chronic hyperglycemia plays a crucial role in the patho-
genesis of diabetic retinopathy (DR). The mechanism of
hyperglycemia-induced retinal damage is still to be eluci-
dated. However, the oxidative stress which represents an
imbalance between excess generation and/or impaired
removal of reactive oxygen species (ROS) have been
suggested to be the key events in the pathogenesis of
diabetic retinopathy. The high content of polyunsaturated
fatty acids, oxygen uptake and glucose oxidation make the
retina more susceptible to oxidative stress than other tissues
[11]. ROS are produced continuously in all cells to support
normal cellular functions. However, excess production of
ROS, or inefficient removal of ROS, could result in
pathological conditions. In addition to ROS, reactive
nitrogen species (RNS) are also a part of normal physio-
logical function, and have great potential to contribute to
oxidative stress [12]. In the presence of superoxide, nitric
oxide spontaneously forms peroxynitrite. Peroxynitrite is
much more reactive than superoxide and nitric oxide and
can exert direct oxidative modifications through one- or
two- electron oxidation processes [13, 14]. Thus, excessive
abundance of ROS and RNS with concurrent dysfunction
of antioxidant defense systems, which includes reducing
enzymes such as superoxide dismutase (SOD), catalase and
glutathione peroxidase (GSH) contributes to oxidative
stress in diabetic retina. Chronic oxidative stress causes
damage to DNA, lipids, proteins, and carbohydrates and
disruption in cellular homeostasis resulting in many disease
processes of clinical interest [15]. Accumulation of dam-
aged molecules and ROS that are not easily removed
contributes not only to the pathogenesis of DR but also to
the resistance of retinopathy to reverse even after good
glycemic control is reestablished- the metabolic memory
phenomenon [16].
Sources of ROS in diabetic retina
Chronic exposure of retinal cells to hyperglycemia causes
overproduction of ROS by activation of different enzymatic
pathways which more likely interact to create the retinal
damage seen in DR (Fig. 1). These sources include but not
limited to NADPH oxidase, mitochondrial electron trans-
port chain (ETC), formation of advanced glycation end
products (AGEs), aldose reductase/polyol pathway, protein
Fig. 1 Hyperglycemia inhibits antioxidant enzymes (superoxide
dismutase (SOD), catalase, glutathione (GSH)) and induces generation
of reactive oxygen species (ROS) and reactive nitrogen species (RNS)
from different sources such as mitochondrial electron transport chain
(ETC), NADPH oxidase, cycloxygenase (COX2), advanced glycation
end products (AGEs), protein kinase C (PKC), polyol pathway and
nitric oxide synthase (NOS). Hyperglycemia-induced generated ROS
and RNS, cause lipid peroxidation and oxidative damage of protein
and DNA resulting in production of biomarkers such as lipid
peroxides and nitrotyrosin. Lipid and protein modification by
hyperglycemia-induced oxidative stress leads to upregulation of
VEGF and activation of NFκB. VEGF and NFκB-dependent signaling
pathway causes retinal vascular and neuronal damage associated with
diabetic retinopathy such as hyperpermeability, leukostasis, apoptosis
and angiogenesis
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kinase C (PKC) activation and uncoupling of endothelial
nitric oxide synthase (eNOS).
NADPH oxidase Recent studies demonstrated that NADPH
oxidase is a major source of ROS in diabetic patients and
animals and retinal endothelial cells treated with high
glucose [17–20]. ROS production by NADPH oxidase has
been linked to the early signs of DR, including increases in
ROS generation, vascular endothelial growth factor
(VEGF) expression, leukostasis and vascular permeability
[17, 21]. Additionally, increased NADPH oxidase activity
and expression of its catalytic subunit NOX2 has been
correlated to increased VEGF expression and retinal neo-
vascularization in a mouse model for ischemic retinopathy
[22]. Phagocyte NADPH oxidase consists of two membra-
nous subunits, large catalytic subunit gp91phox (NOX2)
and small p22phox as well as cytosolic regulatory subunits,
p40 phox, p47phox and p67phox, and the low molecular
weight G protein Rac-1 [23, 24]. Phosphorylation of
p47phox is crucial for the assembly of the complex [25],
while P67phox subunit mediates binding of the complex
with activated Rac [26], both are critical for NADPH
oxidase activation. Vascular endothelial cells express the
same subunits as well as two NOX2 homologues, NOX1
and NOX4 [20]. Previous studies in animal and tissue
culture models have shown that NOX2 is expressed at low
levels in normal retinas and in retinal endothelial cells
maintained under control conditions, but is substantially
increased in retinal vessels of animals with diabetic or
ischemic retinopathy and in retinal endothelial cells
exposed to high glucose or hypoxia [17, 22]. During
diabetes other cells in addition to endothelial cells become
activated and become sources of NADPH oxidase derived
ROS formation. For example, leukocytes are suggested to
regulate retinal edema, ischemia and angiogenesis [27] and
shown to be activated [28–30]and to become source of
oxidative stress [31, 32].
Mitochondrial Electron Transport Chain (ETC) Mitochondria
are the principal endogenous source of superoxide. Hyper-
glycemia disrupts the normal ETC electron flow leading to
electron leak and superoxide generation which induces
mutations in mitochondrial DNA resulting in defective
subunits of the electron transport complexes causing in-
creased superoxide production at physiological concentra-
tions of glucose [2, 33]. Moreover, mitochondrial ROS
suppresses the antioxidant defense mechanisms through
inhibition of SOD and GSH leading to enhanced sensitivity
of retinal cells to oxidative stress since they cannot scavenge
ROS effectively [34–36]. The critical role of mitochondrial
superoxide in DR has been demonstrated by recent studies
using transgenic mice that overexpress mitochondrial SOD.
Overexpression of mitochondrial SOD protected the diabetic
retina from oxidative damage and capillary degeneration
[36]. This indicates that hyperglycemia-induced oxidative
stress can modulate mitochondria function, thus contributing
to the development of DR.
Endothelial Nitric Oxide Synthase (eNOS) eNOS uncou-
pling is an additional source of superoxide generation in
diabetic retina. This occurs, when there is limited amount of
its substrate L-arginine or its co-factor tetrahydrobiopterin.
Uncoupled eNOS use molecular oxygen as a substrate
producing superoxide instead of nitric oxide (NO) [37–39].
Several studies demonstrated the role of eNOS uncoupling
in vascular dysfunctions associated with diabetes which
reversed by supplemental L-arginine treatment [40, 41].
The role of eNOS in DR has been also demonstrated in
human as certain eNOS polymorphism are associated with
DR [42].
Polyol pathway The polyol pathway involves the conver-
sion of glucose into sorbitol by aldose reductase. Sorbitol is
then oxidized to form fructose by sorbitol dehydrogenase.
Increased polyol pathway in diabetes causes depletion of
NADPH. Since NADPH is required for regenerating the
intracellular antioxidant, GSH, increased polyol pathway in
diabetes enhances oxidative stress [43]. The role of this
pathway in the development of DR has been reported in
animal model of experimental diabetes and high glucose-
treated endothelial cells [44, 45].
Advanced glycation end products The AGEs are produced
from strong glycating dicarbonyl compounds such as
methylglyoxal and glyoxal [46]. Chronic hyperglycemia
favors glycation reactions and nonenzymatic glycation
leading to cross-linking of proteins and in turn alterations
in their function, activity, and physical properties. Diabetes,
increases production of AGE and its receptor, RAGE, in the
retinal microvasculature which becomes irreversible In the
late stages of DR [47]. Interaction of AGEs with RAGE
activates PKC-δ and subsequently NADPH oxidase to
enhance oxidative stress in diabetic retina [48]. ROS
generation by AGEs leads to the activation of nuclear
transcriptional factor, NF-kB, [49] which has been linked to
retinal capillary cell apoptosis [50] vascular inflammation
[51, 52] and neovascularization [53, 54].
Protein kinase C activation Activation of PKC is also
considered as a major pathway implicated in the pathogen-
esis of diabetic retinopathy [55, 56]. High glucose levels
increase the release of ROS and the synthesis of diacylgly-
cerol (DAG) increasing the activity of PKC [57]. Activated
PKC has been implicated in changes characteristic of
diabetic retinopathy such as increased vascular permeabil-
ity, neovascularization, endothelial proliferation and apo-
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ptosis, and regulating the action of VEGF [58–60]. There
are cumulative evidences supporting the role of PKC in
ROS-mediated diabetic complications. For example,
diabetes-induced oxidative stress has been shown to be
prevented by PKCβ specific inhibitor (LY53331), and in
mice lacking PKCβ isoform [61–63].
Oxidative stress and vascular changes in diabetic
retinopathy
Diabetic retinopathy is associated with alterations in the
structure and function of retinal microvasculature. For
example, basement membrane thickening, pericyte and
endothelial cell loss, acellular capillary formation [64,
65], microaneurysm, altered blood flow, leukocyte adhe-
sion, hyperpermeability and neovascularization. Many of
these changes have been linked to the oxidative stress-
induced biochemical changes. ROS mediate these changes
by both direct and indirect mechanisms which include
increases in the transcriptional activation of VEGF
expression [66], inflammatory mediators [67, 68], AGEs
formation on collagen which results in basement mem-
brane thickening [69] and modulation of vasoactive
effector molecules such as endothelin-1 and NOS which
contribute to changes in blood flow and vascular perme-
ability [70, 71]. VEGF, a proangiogenic factor, is known
to play a pivotal role in the development of vascular
changes associated with diabetic retinopathy [72, 73].
Hyperglycemia-induced oxidative stress plays a role in
mediating both the expression and pathological effect of
VEGF [17, 74, 75]. For example, our subsequent studies
demonstrated the implication of NADPH oxidase-derived
ROS in the development of vascular dysfunctions in
ischemic retinopathy. We reported abrogation in ROS
formation, retinal expression of VEGF and new vessel
formation in mouse model of ischemic retinopathy when
treated by NADPH oxidase inhibitor [22]. Further studies
on experimental diabetes demonstrated decreased ROS
formation, VEGF expression leukostasis, and vascular
permeability by NADPH oxidase inhibitor or deletion of
its catalytic subunit, NOX2, [21]. Other studies have
reported the beneficial effect of antioxidants such as N-
acetylcysteine in preventing pericyte loss and endothelial/
perivascular cell changes occur early in the pathogenesis
of DR [76]. Moreover, PEDF, an essential antiangiogenic
factor that produced by different retinal cells has been
reported to prevent neuronal derangements, vascular
hyperpermeability and leukostasis and VEGF expression
in diabetic retinopathy via inhibition of ROS formation
[77]. Taken together, these findings confirm the crucial
role of ROS in the development of vascular dysfunction in
DR.
Markers of oxidative stress
Oxidative stress induces biochemical changes in the serum and
target organs of diabetic patients including severe lipid
peroxidation, protein oxidation, and oxidative DNA damage
and changes in their antioxidant status (Fig. 1). Thus,
identification of the by-products induced by oxidative stress
in serum, vitreous body, aqueous humor, fibrovascular tissue
on the retinal surfaces and urine of diabetic patients could be
in favor of predicting, diagnosis and prevention of microvas-
cular complications of diabetes such as retinopathy and
nephropathy. Oxidative stress parameters include malondial-
dehyde (MDA), thiobarbituric acid reacting substances
(TBARS), conjugated diene (CD), advanced oxidation protein
products (AOPP), protein carbonyl, 8-hydroxydeoxyguanosin
(8-OHdG), nitrotyrosine, and F(2) isoprostanes. Several
studies demonstrated a marked increase in these products in
serum/retinas of diabetic patients or experimental animals and
significantly higher in patients or animals with DR than in
diabetic patients/animals without DR. Additionally, ameliora-
tion of the antioxidant status plays a crucial role in
development of DR.
Fig. 2 Table depicting biomarkers of neuronal death that have been
reported in human patients with diabetic retinopathy and in rodent
models of this disease
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Lipid peroxidation
Lipid peroxidation of cellular structures, an oxidative
stress-induced activity, is thought to play an important role
in complications of diabetes mellitus, especially in diabetic
retinopathy. Measurement of TBARS, MDA or CD
provides a convenient assessment of lipid hydroperoxide
(LHP) concentration in serum. CD is the initial formation of
lipid peroxide while MDA is a decomposition product of
peroxidized polyunsaturated fatty acids. The elevated levels
of Poly Unsaturated Fatty Acids (PUFAs) and increased
rate of glucose oxidation in diabetes make the retina
susceptible for oxidative stress and lipid peroxidation.
Increased lipid peroxides has been demonstrated in serum
of diabetic patients with vascular complications [78–85].
Lipid peroxidation increases also in retinas of diabetic
animals and mouse model of ischemic retinopathy [17, 22].
Compared with healthy subjects, diabetic patients demon-
strate significantly higher levels of lipid peroxidation
products [86–90]. Additionally, patients with features
of DR are found to have much more lipid peroxidation
products compared with those without DR [85, 86].
Studies by Armstrong et al., demonstrated a statistically
significant correlation between the increasing serum lipid
peroxidation levels and prevalence of retinopathy in
diabetic patient [91] and reduction in retinal cell number
in streptozotocin (STZ)-induced diabetic rat model [92].
Similar results have observed by Augustin et al. [93, 94] in
patients with PDR where they demonstrated a significant
increase in lipid peroxidation in the vitreous and epiretinal
membranes.
In addition to the previous markers of lipid peroxidation
several studies have demonstrated the role of oxidative
stress-induced modification of low density lipoprotein in
the pathogenesis of DR [95–97]. Fredrikson et al. [98]
reported that patients affected by retinopathy had signifi-
cantly higher levels of autoantibodies against apolipopro-
tein B peptides than patients without retinopathy. Thus,
autoantibodies against oxidized LDL antigens might also
reflect disease severity and the risk of developing vascular
complication of diabetes including DR.
A major step regarding the measurement of lipid
peroxidation products came with the discovery of F2-
isoprostanes [99, 100]. The F2-isoprostanes are a family
of PG (prostaglandin)-like compounds produced by non-
enzymatic peroxidation of arachidonic acid. Of these, 8
epi PGF2a (also known as 8 iso PGF2a or 15-F2t-
isoprostane) has received most attention because it has been
shown to possess certain adverse biological activities [101–
104]. Circulating 8 epi PGF2a is mainly present bound
to phospholipids in situ and is released by the action of
phospholipase A2 [105] and has proved a reliable marker of
oxidative stress in human body. However, the quantification
of urinary 8 epi PGF2a has been proposed as being
superior to the measurement of circulating 8 epi PGF2a
levels, as it is believed to represent a more accurate systemic
index of oxidative stress [106]. In their study on human
retinas obtained from healthy donors Nourooz-Zadeh and
Pereira provided the first direct evidence for free-radical-
catalyzed peroxidation of AA in retinal tissue by detecting
esterified F(2)-IPs in human retina. Thus they proposed
analysis of F(2)-IPs for studying the implications of
oxidative injury in various diseases of retina, including
diabetic retinopathy and age-related macular degeneration
[107].
Biomarkers of DNA and protein oxidative damage
8-hydroxydeoxyguanosine (8-OHdG) ROS can cause DNA
damage and base modifications. 8-OHdG, an oxidized
nucleoside of DNA, results from oxidation of guanine
residues and is frequently used as DNA lesion marker.
Higher levels of 8-OHdG were observed in the mononu-
clear cells, urine, pancreatic islet and mitochondrial DNA
from diabetic patients [108–112] and in kidney tissues of
streptozotocin-induced diabetic rats [113]. Moreover, the
content of 8-OHdG in the urine, serum and mononuclear
cells of patients with type 2 diabetes with either retinopathy
or nephropathy were much higher than those in patients
without complications. [86, 114, 115]. Therefore, the
contents of 8-OHdG in serum could act as a sensitive
biomarker for the diabetic retinopathy.
Carbonylated proteins Proteins can also be modified and
become cytotoxic by ROS and RNS, thus contributing to
the development of DR. There is association between the
elevated biomarkers of protein oxidation with aging and
different diseases such as Alzheimer’s, diabetes mellitus
and cancer [86, 116, 117]. Protein carbonylation and
nitration have attracted a great deal of attention due to its
irreversible and unrepairable nature which may serve as an
important biomarker in DR.
Carbonylated proteins are marked for proteolysis by the
proteasome but can escape degradation and form high-
molecular-weight aggregates that accumulate with age.
Such carbonylated aggregates can become cytotoxic and
have been associated with a large number of diseases and
age-related disorders, including Parkinson’s disease, Alz-
heimer’s disease, cancer, cataractogenesis, diabetes, and
sepsis [118, 119], for review see [120]. The implication of
protein carbonylation in reflecting the severity of diabetes
and its complication has been investigated by many
researchers [86, 121, 122]. There is a positive correlation
between protein carbonylation and the clinical severity of
DR. For example, compared to healthy individuals diabetic
patients have significantly increased levels of carbonylated
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proteins. Furthermore, patients with DR show higher level
of protein carbonylation more than in diabetic patients
without DR [86, 123].
Protein nitration Nitrotyrosin is additional marker for
oxidative damage of protein that disrupts its normal
functions. Several studies have demonstrated that diabetes
increases protein nitration in retinas of experimental
animals [17, 124, 125]. Nitrotyrosine is an oxidative protein
modification which formed from the reaction of free or
protein-bound tyrosine with reactive nitrogen species such
as free radical nitrogen dioxide [126] and peroxynitrite
[127] and has been used as a marker of oxidative stress in
retina of experimental animals [17, 124]. Although tyrosine
nitration has been associated with development of diabetic
and ischemic retinopathies little is known about the targets
of tyrosine nitration in retina and the role nitration may play
in the pathophysiology of diabetic retinopathy. Recently,
Zhan et al. identified some proteins that are nitrated in
diabetic rat retina and in rat retinal Müller cells grown in
high glucose which could be linked to retinal neovascula-
rization[125]. Additionally, subsequent studies by El-
remessy et al., have shown that peroxynitrite-induced
tyrosine nitration correlates with accelerated retinal endo-
thelial cell death, breakdown of the brain-retinal barrier, and
accelerated neuronal cell death in models of experimental
diabetes and neurotoxicity and human diabetes [124, 128–
130]. Recent reports demonstrated that accumulation of
nitrosylated protein in peripheral blood monocyte of
diabetic patients is an emerging marker that reflects
oxidative stress-induced protein damage. [131, 132]. Julius
et al., 2009 reported that diabetic subjects accumulate
significant amount of nitrosylated protein in peripheral
blood monocyte and this is positively correlated with the
severity of diabetic microangiopathy such as nephropathy
and retinopathy [132]. Thus, targeting tyrosine nitration
represents potentially effective therapeutic strategy in
attenuating retinal vascular neurodegenerative diseases.
Advanced oxidation protein products (AOPP) Serum level
of AOPP is also a novel protein oxidation marker which has
been described by different investigators [133–136]. They
are elevated in patients with renal insufficiency and
diabetes mellitus [137–139]. Additionally, the level AOPP
in diabetic patients with features of DR was reported to be
significantly higher than in diabetic patients without DR
[86, 136].
In addition to the previous markers of oxidative damage
of protein and DNA in diabetic patient, mass spectrometric
quantification of amino acid oxidation products and
glutathionylated hemoglobin has been proposed to serve
as markers for the oxidative stress in diabetic patients, in
particular those with complications such as DR [140, 141].
Antioxidant status
The antioxidant status of diabetic patient plays a crucial
role in producing oxidative stress and development of
vascular complications. ROS generation is inhibited by an
intracellular enzymatic system composed mainly of gluta-
thione peroxidase (GPx), SOD and catalase (CAT). All
serum antioxidants are usually measured together as total
antioxidant status (TAS). The reports about the status of
antioxidants and antioxidant enzymes in diabetic patients
are very contradictory, both increases and decreases of
antioxidant activity have been reported [142–145]. Gener-
ally, TAS has been shown to be significantly lower in
patients with proliferative retinopathy than in diabetics not
developing retinopathy [146]. Antioxidants SOD and
vitamin C decrease with the progression of the disease,
however GPx tends to increase in the later part of the
disease [147]. Kesavulu et al., in their study they found that
among the erythrocyte antioxidant enzymes, CAT activity
was significantly increased in all the diabetics compared to
controls, however, there was no difference in the CAT
activity between the diabetic patients with or without
microvascular complications (MVC) such as diabetic
retinopathy or nephropathy. In contrast, GPx activity was
significantly decreased in the diabetic patients compared to
controls, and further decreased in the diabetics with MVC
compared to those without the complications. The SOD
activity in diabetic patients was not much different from
that of non diabetic controls, but a significant decrease in
SOD activity was observed in diabetic patients with MVC
compared to those without these complications [85]. The
total thiol level as a marker of antioxidant status in diabetics
has also shown to be significantly decreased in patient with
DR than those without DR [136]. An inverse relation
between the level of GSH and HbA1c was also reported in
diabetic patients indicating reduction in the antioxidant
status in poorly controlled diabetics [141]. Additionally,
nonenzymic antioxidants such as vitamin C, vitamin E, and
β-carotene that exist biologically for the regulation of redox
homeostasis are also depressed by diabetes [148]. There-
fore, the level and activity of specific antioxidant enzymes
compared to other enzymes that do not match to develop-
ment of DR could be predictive for the susceptibility to
develop DR in diabetic patients.
Oxidative stress related gene polymorphism
There are several studies showing that vascular complica-
tions of diabetes develop only in genetically susceptible
patients [149–151] and hyperglycemia by itself is not
sufficient for the development of diabetic vascular disease.
There is tendency to have familial clustering of diabetic
nephropathy and coronary vascular disease (CVD). Addi-
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tionally, there is a significant ethnic difference in the
incidence of CVD in subjects with diabetes that could not
be explained by differences in conventional cardiovascular
risk factors (UK Prospective Diabetes Study Group 1998).
Various candidate genes that affect the oxidative stress such as
manganese mitochondrial superoxide dismutase (Mn-SOD),
endothelial nitric oxide synthase (eNOS), angiotensin-
converting enzyme, glutathione peroxidase, superoxide
dismutase and haptoglobin demonstrate functional polymor-
phisms which correlated with the increased susceptibility to
vascular diseases and diabetes [152–156].
Manganese superoxide dismutase (MnSOD) polymorphism
Hovnik et al, 2009 investigated polymorphic markers in
genes encoding enzymes regulating production of reactive
oxygen species in association with diabetic retinopathy (DR)
or diabetic nephropathy (DN) in one hundred and twenty four
patients with type 1 diabetes and matched for sex, age and
duration of diabetes. A positive association of MnSOD
genotype Val/Val with diabetic retinopathy but not with
diabetic nephropathy was demonstrated [157]. Moreover,
the association of diabetic retinopathy with single nucleotide
polymorphisms (SNPs) on MnSOD was investigated and a
statistically significant association of MnSOD Ala16Val
polymorphism with diabetic retinopathy was found com-
pared with the diabetic control. Additionally, the Ala(-9)Val
[156] and VV genotype of the V16A [155] polymorphism of
the Mn-SOD gene are also reported to be significantly higher
in patients with DR retinopathy in Chinese and Caucasians
type 2 diabetic patients respectively.
Haptoglobin polymorphism Haptoglobin (Hp) is a
hemoglobin-binding serum protein. It is found at levels of
30–300 mg/dL in normal human serum [158]. However,
serum level of Hp shows 3- to 8-fold increase during the
acute phase reaction and in response to injury [159]. Free
hemoglobin (Hb) is considered as an extremely potent pro-
oxidant agent which catalyzes various oxidative and
peroxidative reactions [160]. Haptoglobin (Hp) plays an
essential role in capturing free Hb, thus preventing
oxidative tissue damage mediated by free Hb. For example,
Hp has been demonstrated to inhibit Hb-induced linolenic
acid and low-density lipoprotein (LDL) oxidation [161].
Additionally, Hp knockout mice have shown to be more
prone to oxidative tissue damage such as renal damage and
endothelial dysfunction [162]. Recent reports demonstrated
that a polymorphism in the haptoglobin (Hp) gene is an
independent risk factor for diabetic vascular disease [153,
154]. In man, there are two alleles for Hp, denoted 1 and 2,
giving rise to three major phenotypes. Individuals homo-
zygous for the 1 allele express the Hp1-1 phenotype at the
protein level. Individuals homozygous for the 2 allele
express the Hp2-2 phenotype, whereas heterozygotes
express the Hp2-1 phenotype. Nakhoul et al., 2000 have
observed a marked decrease in the prevalence of diabetic
retinopathy in patients with Hp1-1 phenotype compared
with patients with the Hp2-1 and Hp2-2 phenotypes [163].
Hp1-1and Hp1-2 types have been found to have signifi-
cantly higher levels of serum vitamin C [164], lower serum
iron, and lower circulating oxidized LDL (oxLDL)/LDL
ratios compared with those with the Hp2-2 [165, 166].
Thus, antioxidant therapy may be more beneficial in
diabetic patients with the Hp2-2 phenotype as compared
with those with the Hp1-1 phenotype. Furthermore, a
highly significant increase in retinal capillary basement
membrane thickness was observed in mice with
streptozotocin-induced diabetes with the Hp 2 genotype.
These data provide important support for association
studies done in humans showing an increased prevalence
of diabetic retinopathy in individuals with the Hp 2
genotype [167].
eNOS gene polymorphism Polymorphisms of eNOS gene
have been reported to be associated with multiple health
conditions including DR, hypertension, nephropathy, and
cardiovascular diseases in several ethnic groups. Several
studies demonstrated the association between certain
eNOS polymorphism with DR in human [42, 168,
169]. For example, the eNOS 4b/b [42] or 4a/b [168]
polymorphism demonstrate increased eNOS expression
and activity and associated with sever DR. On the other
hand, homozygous deletion of eNOS 4a/a causes reduc-
tion in eNOS expression and activity and susceptibility to
DR [170].
Inflammation related markers
In addition to oxidative stress related biomarkers, genera-
tion of ROS in diabetic patients is known to initiate a
cascade of signaling pathways responsible for the inflam-
matory component of DR. This includes activation of
NFκB and up-regulation of genes responsive to inflamma-
tory processes such as adhesion molecules [21, 52, 171,
172]. Golubnitschaja et al., 2005 have studied the alteration
in inflammatory related genes in mononuclear blood cells
(MBCs) isolated from diabetic patients with and without
active retinopathy. They found significant increase in the
expression of recoverin in diabetic patients compared to the
control group. “Real-Time”-PCR showed that recoverin
levels were positively correlated with the stage of DR and
with the activity of serum matrix metalloprotinases (MMPs)
[173]. Thus, identification of inflammation related bio-
markers in isolated MBCs and serum of diabetic subjects
may be helpful for the prediction of active proliferative
retinopathy in diabetics.
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Neuronal death and diabetic retinopathy
The preceding section of this chapter describes the complex
vascular changes that accompany diabetic retinopathy. For
many years, the disease was considered primarily vascular
in nature. Beginning in the late 1990s, however, informa-
tion about the neuronal components of diabetic retinopathy
emerged. Several excellent reviews published in the last
decade have summarized the evidence that neurons,
particularly retinal ganglion cells, are vulnerable and die
in diabetic retinopathy [5–7, 174, 175]. Loss of color [176,
177] and contrast [178, 179] sensitivity are early signs of
neural retinal dysfunction in humans that occur within
2 years of diabetes onset. Bresnick proposed that diabetic
retinopathy is a primary neurosensory disorder that pre-
cedes vasculopathy by many years [8, 180]. It is notewor-
thy that as early as the 1960’s Wolter [181] and Bloodworth
[182] described loss of retinal neurons in diabetic patients.
However, owing to the more easily recognizable vascular
features as viewed via ophthalmoscopy, these observations
were largely overlooked. More sophisticated electrophysi-
ological studies using macular or focal ERG (FERG),
which can detect electrical responses of ganglion cells,
showed ganglion cell dysfunction early in diabetes [183].
Though FERG is not used widely clinically, important
information has been forthcoming from several studies.
Greco et al. [184] used FERG in prepubescent diabetic
children and found that ganglion cell function was
significantly impaired, while other cells such as photo-
receptors appeared unaffected. Others have reported similar
findings, including ganglion cell dysfunction in IDDM
patients without vasculopathy [185, 186]. Other investiga-
tions using ERG, dark adaptation, contrast sensitivity, and
color vision tests have provided convincing functional
evidence that neural retina function is compromised
oftentimes before the onset of vascular lesions in humans
[187–192].
Markers for apoptosis in human tissues
The relevance of this functional evidence of neuronal
degeneration in diabetic retinopathy has been borne out
by molecular and biochemical analyses of the retinas of
human patients. Barber et al. used post-mortem tissues from
human patients with diabetic retinopathy and reported for
the first time that ganglion cells die in this disease and do
so via an apoptotic mechanism [193]. Subsequent studies
by Abu El-Asrar used eyes from human diabetic patients
and confirmed the expression of several pro-apoptosis
molecules (caspase-3, Fas, and Bax) emphasizing the
vulnerability of these cells [194]. They also found strong
immunoreactivity for ERK1/2 in the inner nuclear layer of
diabetic retinas as well as the nerve fiber and ganglion cell
layers. This group extended their findings by examining
additional anti- and pro-apoptotic markers in humans and
showed that ganglion cells in diabetic and non-diabetic
retinas express the anti-apoptotic molecules Cox-2, Akt,
and Mcl-1. Retinal ganglion cells express the proapoptotic
molecule Bad in response to diabetes-induced neuronal
injury; diabetic retinas also show upregulation of the
mitochondrial proteins cytochrome c, and AIF (Fig. 2)
[195]. Human tissue from diabetic patients has also been
shown to express connective tissue growth factor (CTGF),
CD105 and gelatinase B, and ganglion cells and microglia
were the sites of immunoreactivity [196]. Other investigators
have provided additional support that the death of neurons in
human diabetic retinas is mediated via mitochondria- and
caspase-dependent cell-death pathways [197].
These data collected from human tissues provide strong
evidence that neurons die in diabetic retinopathy and that
they do so via an apoptotic mechanism, however no
comprehensive reports are available indicating specific
markers that predict neuronal cell death in human subjects.
By definition, biomarkers should reflect a change in
expression or state of a protein that correlates with the risk
or progression of disease, or with the susceptibility of the
disease to a given treatment. The field of biomarker
research is just emerging and the published reports on
biomarkers for neuronal cell death, especially in humans
with diabetic retinopathy, are limited.
Model systems to investigate biomarkers of neuronal death
in diabetic retinopathy
To understand genes/proteins whose expression is changed
in diabetic retinopathy, investigators have relied extensively
on the use of model systems including in vivo animal
models and in vitro systems. Much of the work has focused
on ganglion cells since they are vulnerable in human
diabetic retinopathy. Schmidt and colleagues postulate that
ganglion cells are particularly susceptible to neurodegener-
ative disease because of their high metabolic rate [198].
They note that ganglion cells have very long axons
extending from the cell soma, through the lamina cribrosa
(LC) and beyond. Moreover, unlike many neurons they are
unmyelinated from the retina to the LC and only thereafter
become myelinated. This reversed myelination pattern leads
to an impedance mismatch that consumes considerable
energy.
Studies in diabetic rats
Animal models of diabetic retinopathy include the well-
characterized streptozotocin-induced diabetic rat. In rats,
diabetes accelerates retinal neuronal cell death and inhibits
neurite regeneration via an apoptotic mechanism that
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involves upregulation of Bax, a pro-apoptotic gene [199].
In the rat model, a number of inflammatory markers have
been shown to be upregulated concomitant with ganglion
cell death. These markers include interleukin (IL)-18 [200],
IL-1β [124, 200], vascular endothelial growth factor
(VEGF) [124], tumor necrosis factor-α (TNF-α) [124,
200], activated p38 MAP kinase [124]. Related to these
observations are the data showing a significant ∼30%
increase in glucosylceramide levels in diabetic rats com-
pared to controls [201]. These investigators were the first to
demonstrate that augmented glycosphingolipid metabolism
may contribute to the neuronal pathology of diabetic
retinopathy and may serve as an important and relevant
biomarker in human patients. Nakazawa et al have shown
that anti-inflammatory agents (statins) can prevent ganglion
cell death in ischemic/reperfusion rat models [202]. Zhang
and co-workers observed an increase in the receptor for
erythropoietin, a glycoprotein hormone that controls eryth-
ropoiesis in diabetic rats [203]. Another interesting mole-
cule whose expression is decreased in the diabetic rat retina
is SERPINA3K, an extracellular serine proteinase inhibitor
(Fig. 2) [204]. This observation is noteworthy because
SERPINA3K prevents intracellular calcium overload and
calcium is well known to trigger neuronal death. Several
groups have demonstrated that insulin mediates a pro-
survival pathway in retinal neurons. It has been demon-
strated that insulin receptor signaling diminishes with
increased diabetes-induced apoptosis [205]. Very recently
Fort and colleagues have applied complementary proteomic
and genomic techniques and discovered that the proteins of
the crystallin superfamily are increased dramatically in
early diabetic retinopathy [206]. Their data suggest that the
changes observed in crystallins are greater than other
changes described so far in diabetic retinopathy. The work
also emphasizes the power of the ‘omic’ approaches
(genomic, proteomic, etc) to uncovering biomarkers for
diabetic retinopathy.
As data are accumulated about molecules whose expres-
sion changes in diabetic retinopathy it is tempting to target
them as a means to protect against deleterious consequen-
ces of diabetes. However, caution must be exercised
regarding this strategy. A case in point is VEGF. VEGF
plays key role in vasculogenesis and has been an anti-
angiogenic target in treating a number of blinding diseases
[207]. Recently VEGF-A has been recognized as an
important neuroprotectant in the central nervous system
[208]. Nishijima and co-workers used a model of ischemia-
reperfusion injury and found that VEGF-A exposure
resulted in a dose-dependent reduction in retinal neuron
apoptosis [209]. Indeed, chronic inhibition of VEGF-A
function in normal adult animals led to a significant loss of
retinal ganglion cells yet had no observable effect on
several vascular parameters. Their findings have important
implications for both neural pathologies and ocular vascular
diseases, particularly diabetic retinopathy.
Studies in diabetic mice
Mice constitute a powerful model system for understanding
disease mechanisms, particularly the influence of genetic
mutations on the progression of pathology. The field of
diabetic retinopathy is no exception and a number of mouse
models have proven informative with respect to gene/
protein changes that occur in this disease. One of the most
useful models is the Ins2Akita/+ mouse model, which has
proven relevant to and useful for studies of diabetic
retinopathy [210–214]. The Ins2Akita/+ mouse has a point
mutation of the Insulin2 gene leading to hypoinsulinemia
and hyperglycemia in heterozygous mice by ∼4 weeks
[215]. Homozygosity for the mutation is embryonically
lethal. Over a period of several weeks (∼10–25 weeks),
heterozygous mice demonstrate marked retinal alterations
including ∼20–25% reduction inner plexiform layer thick-
ness, a ∼16% reduction of inner nuclear layer thickness and
a ∼25% reduction in the number of cell bodies in the RGC
layer [211, 212, 214]. The cell death appears to occur via
apoptosis as evidenced by data from TUNEL assays [214]
and detection of active caspase 3 [211]. Oshitara and
colleagues have utilized the Ins2Akita/+ mouse to examine
the role of ER stress in diabetic retinopathy [174]. ER stress
refers to the phenomenon whereby misfolded proteins
aggregate in the ER lumen activating the unfolded protein
response (UPR). The aim of the UPR is to alleviate ER
stress, restore ER homeostasis and prevent cell death.
Activation of the response is mediated by GPR78 (BiP,
binding protein), which dissociates from three resident
proteins: inositol requiring ER-to-nucleus signal kinase
(IRE)1, activating transcription factor (ATF) 6 and
soluble-stranded RNA-activated kinase (PKR)-like ER
kinase (PERK) [216]. Studies of the Ins2Akita/+ mouse
demonstrated that ER stress is involved in the death of both
retinal neurons and vascular cells in diabetic eyes as
manifested by increased expression of BiP as well as
PERK, ATF6, IRE1 (Fig. 2) [174]. These data are particularly
interesting to our group because of our work showing that
(+)-pentazocine, a ligand for sigma receptor 1 (σR1),
affords profound neuroprotection in the Ins2Akita/+ mouse
[214]. σR1 is a molecular chaperone protein that resides at
the ER-mitochondrial membrane and interacts with BiP. We
are currently examining the expression of ER-stress related
genes and our preliminary data suggest that expression of
PERK, ATF6 and IRE1 as well as downstream effectors
CHOP, BCL2 are increased in the diabetic retina, but
expression returns to normal upon sustained treatment with
(+)-pentazocine (manuscript in preparation). ER stress
genes/proteins may prove to be important additional
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biomarkers of neuronal death in diabetic retinopathy and
reducing or blocking ER stress may be a potential therapy
for preventing the onset and the progression of this disease.
Other mouse models, in which diabetes occurs endoge-
nously, have demonstrated neuronal degeneration as well.
The retinas of hyperglycemic, hyperlipidemic (HGHL,
apolipoprotein E(−/−) db/db) have been examined for
advanced glycation endproducts (AGE) and receptors for
these endproducts (RAGE) [217, 218]. The mice demon-
strate early inner retinal neuronal dysfunction, manifested
by prolonged latencies of the oscillatory potentials and b-
wave as well as acellular capillaries and pericyte ghosts.
The investigators found AGEs in the vitreous and associ-
ated with the inner limiting membrane formed by the
Müller cell endfeet. They noted that attenuation of the
RAGE axis with soluble RAGE ameliorated neuronal
dysfunction and reduced the development of capillary
lesions in these mice. The KKAY mouse is another model
that is useful for studies of Type 2 diabetes. As with the
Ins2Akita/+ and the db/db mice, the KKAY mouse develops
retinal neuropathy and microangiopathy [219], and hence
should prove useful for analyses of biomarkers especially in
determining whether there are differences in gene expres-
sion associated with this model of Type 2 diabetes versus
those that more closely mimic Type 1. Other groups have
induced diabetes in mice using streptozotocin and exam-
ined effects on neuronal function [220]. When the mice are
not maintained on insulin, which is known for its neuro-
protective properties [205, 221, 222], death of ganglion
cells has been documented [220]. Using this model
Kurihara and colleagues examined the relationship of the
rennin-angiotensin system (RAS) with synaptophysin, a
synaptic vesicle protein [222]. They examined the
streptozotocin-induced mouse model have examined syner-
gistic effects of diabetes neuronal activity in streptozotocin-
induced diabetic mice by ERG. Using a variety of
molecular and biochemical approaches they found that
diabetes was associated with a significant increase in retinal
production of angiotensin II and AT1R together with ERK
activation. They observed ERG changes and a reduction in
the level of synaptophysin protein (but not mRNA levels).
Based on these observations, they treated the diabetic mice
with the angiotensin II type 1 receptor (AT1R) blocker
telimsartan or valsartan and found that they could reverse
the ERG changes and the decreased synaptophysin. Other
studies have used and other genetic defects. For example,
mice with a defect in the cystathionine-β-synthase gene
develop hyperhomocysteinemia [223]. Increased levels of
homocysteine are implicated in several ocular diseases
including diabetic retinopathy [224–226] and glaucoma
[227, 228]. In the cbs+/− mutant mice, retinal ganglion
cells die by apoptosis [229] and diabetes accelerates the
retinal neuronal loss in these mice [230].
Studies in cell lines and purified ganglion cells
While in vivo models are critical for advancing our
understanding of biomarkers in neuronal death associated
with diabetic retinopathy, there is a place also for studies
using a single cell type. Indeed initial screenings to detect
biomarkers and postulate therapies are well-served by the
availability of appropriate in vitro model systems. Fortu-
nately, the field of diabetic retinopathy research has several
models to exploit for these purposes.
The rat R28 retinal precursor cells, immortalized with
the 12S, nontumorigenic portion of the adenovirus E1A
gene, provide researchers with an inexhaustible supply of
cells for studying structural and functional differentiation in
the retina. The R28 cells were developed in the laboratory
of Dr. Gail Seigel and have been used extensively to
analyze mechanisms of diabetes-induced neuronal cell
death [231]. Notable among the studies are discoveries of
several biomarkers for retinal neuronal cell death that may
have implications for diabetic retinopathy including sphin-
golipids [201], p44/p42 mitogen-activated protein kinase
[232], glucosamine-induced PERK activation [233], hexos-
amines [233], advanced glycation end products (AGE)
[234], IL-1β [235], and glutamate receptor/calcium homeo-
stasis [236] to name a few.
Useful also for studies of retinal neuronal cell death is
the RGC-5 cell line. In 2001, Krishnamoorthy and
colleagues published the development of the RGC-5 cell
line [193]. It was reportedly derived by transforming
postnatal day 1 rat retinal cells with ψ2 E1A virus [237].
Recent re-characterization of the RGC-5 cell line suggests
that it is actually of mouse origin [238]. When originally
described, the RGC-5 cells expressed Thy-1.2, Brn-3C,
neuritin, NMDA-R1 and GABA receptors, which are
neuronal markers characteristic of intact ganglion cells.
RGC-5 cells do not express glial fibrillary acidic protein
(GFAP) a marker of glial cells. In early passage, the cells
were sensitive to glutamate (5 mM) and that sensitivity
could be increased if the cells were treated with succinyl
concanavalin A (S Con A) [237]. Interestingly, recent
studies by Van Bergen and co-workers showed that RGC-5
cells no longer express the ganglion cell marker protein Thy
1.2, whether differentiated using S Con A or not [238]. Our
laboratory obtained this cell line shortly after it was first
available in 2001 and our stock continues to express
Thy1.2, however the sensitivity to homocysteine, glutamate
and oxidative stress is diminished [239]. There are over 100
papers published since 2001 using the RGC-5 cells. Many
studies explore alterations of genes/proteins associated with
diabetic retinopathy. Indeed, in the last 12 months, there
have been over 30 publications using these cells for such
analyses. Many of these reports used the RGC-5 cell to
determine gene/protein alterations or therapeutic interven-
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tion strategies under conditions intended to mimic diabetes.
For example, Osborne et al. exposed the cells to retinal
ischemia and oxidative stress to determine effects of
latanoprost acid [240]. Other studies have examined the
PI3-kinase/Akt pathway [241], 5-S-GAD as a neuroprotec-
tant [242], bevacizumab toxicity [243], the ERK1/2 path-
ways [244], and tafluprost [245].
The RGC-5 cell lines proliferate quickly and are not
neuronal in appearance. However, when incubated with the
protein kinase inhibitor staurosporine, a more neuronal
phenotype is achieved. RGC-5 cells treated with 316 nM
staurosporine express neurites, become postmitotic and non-
apoptotic, and alter their kinase phosphorylation patterns
[246, 247]. In addition, they are positive for a number of
neuronal markers including Thy 1.2 [246]. Staurosporine-
induced differentiated RGC-5 cells are sensitive to oxidative
stress induced by hydrogen peroxide, ischemia, glucose
deprivation and plasminogen activators [248, 249]. Recent
studies in our lab examined the susceptibility of these
differentiated RGC-5 cells to homocysteine. We observed that
when differentiated, the cells increase expression of active
caspase-3, which is not observed in non-staurosporine-treated
cells [239]. The staurosporine-treated cells were not suscep-
tible to homocysteine until applied in exceedingly high
dosages. Thus, RGC-5 cells are a useful neuronal model, but
data must be interpreted cautiously acknowledging the
limitations of the in vitro system.
A more labor-intensive method to study proteins/genes
in ganglion cells that are affected by diabetic retinopathy is
to purify the cells from the intact animal. Our laboratory
has adapted methodology from the Barres laboratory [250]
to immunopan ganglion cells from neonatal mice [251].
The cells are viable for 22 days when maintained in a
supplemented neurobasal media [251]. They extend neurite
processes characteristic of ganglion cells. Using these cells
we have been able to demonstrate exquisite sensitivity to
oxidative stress, a factor implicated in diabetic retinopathy,
that leads to upregulation of the xCT protein component of
the glutamate-cystine exchanger system xc
− [251]. Owing
to the role of this exchanger in generation of the antioxidant
glutathione, it likely represents a mechanism to enhance
ganglion cell survival under stress. The primary ganglion
cell cultures are sensitive to physiologically-relevant levels
of glutamate and homocysteine; they die by an apoptotic
mechanism when exposed to these excitotoxins, a phenom-
enon that is inhibited by treatment with the σR1 ligand (+)-
pentazocine [252]. We have preliminary evidence that when
primary ganglion cells are treated with the oxidative
stressor xanthine:xanthine oxidase, numerous pro-
apoptotic genes are upregulated including Bad, Bak, Fas-
L and Trail [Ha et al., manuscript in preparation]. These data
are noteworthy since xanthine oxidase is involved in free
radical production in type 1 diabetic human patients [253].
We have used the primary ganglion cells to explore
expression of a number of genes/proteins and found them
to reflect the expression in intact mouse retina faithfully
[254–257]. Studies are underway to explore ER stress
genes whose expression is altered as a consequence of
factors associated with diabetic retinopathy.
In Summary, diabetic retinopathy in human patients is
characterized by neuronal and vascular alterations that can
ultimately lead to devastating vision loss. Oxidative stress is
crucial in mediating vascular dysfunctions associated with DR
via modification of retinal lipids, proteins and DNA. This
effect is associated with switching on various signaling
pathways that include but not limited to upregulation of
angiogenic factors, activation of NF-kB and production of
inflammatory mediators. Therefore, early detection of the
biochemical effect of oxidative stress such as by-products of
lipid peroxidation, DNA and protein oxidative damage in
diabetic patients could serve as biomarkers which may be
effective in early prediction and treatment of DR. Interesting-
ly, variations in oxidative stress related genes among diabetic
patients plays also a role as an additional risk factor that makes
some patients more vulnerable to develop DR than others.
Thus, gene polymorphism could be also used as predictive
marker for increased susceptibility to develop DR in diabetic
patient. There is strong evidence from analysis of human
tissue that retinal ganglion cells are particularly susceptible in
diabetic retinopathy. Investigators are using a variety of model
systems, both in vivo (rat and mouse) and in vitro (ganglion
cell lines and primary cultures) to determine key genes/
proteins whose expression is changed under diabetic con-
ditions with the aim of uncovering the most promising targets
for successful intervention. Using relevant in vitro models and
confirming the data in relevant in vivomodels should pave the
way for important biomarkers to be identified and targeted in
treating this disease.
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